555 POSTER The PARP inhibitor, ABT-888 overcomes resistance in temozolomide refractory breast and prostate xenograft tumors implanted in metastatic sites in vivo

Autor: Palma, J., Rodriguez, L., Wang, Y.W., Bukofzer, G., Hickson, J., Penning, T., Giranda, V., Rosenberg, S., Frost, D., Donawho, C.
Zdroj: In EJC Supplements 2008 6(12):175-175
Databáze: ScienceDirect